Patents by Inventor Michael R. Costa

Michael R. Costa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Marks as modifers of the PTEN pathway and methods of use
    Patent number: 8273536
    Abstract: Human MARK genes are identified as modulators of the PTEN pathway, and thus are therapeutic targets for disorders associated with defective PTEN function. Methods for identifying modulators of PTEN, comprising screening for agents that modulate the activity of MARK are provided.
    Type: Grant
    Filed: June 18, 2004
    Date of Patent: September 25, 2012
    Assignee: Exelixis, Inc.
    Inventors: Michael R. Costa, Garth Joseph McGrath, Kim Lickteig, Timothy S. Heuer
  • MAPKs as modifiers of the rac, axin, and beta-catenin pathways and methods of use
    Patent number: 8067180
    Abstract: Human MAPK genes are identified as modulators of the Rac, axin, and beta-catenin pathways, and thus are therapeutic targets for disorders associated with defective Rac, axin, and beta-catenin function. Methods for identifying modulators of Rac, axin, and beta-catenin, comprising screening for agents that modulate the activity of MAPK are provided.
    Type: Grant
    Filed: November 24, 2003
    Date of Patent: November 29, 2011
    Assignee: Exelixis, Inc.
    Inventors: Lisa C. Kadyk, George Ross Francis, Steven Brian Gendreau, Emery G. Dora, III, Michael R. Costa, Kim Lickteig
  • SPHKS as modifiers of the p53 pathway and methods of use
    Publication number: 20080241131
    Abstract: Human SPHK genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of SPHK are provided.
    Type: Application
    Filed: April 3, 2008
    Publication date: October 2, 2008
    Applicant: Exelixis Inc.
    Inventors: Lori S. Friedman, Gregory D. Plowman, Michael R. Costa, Danxi Li, Roel P. Funke, Tak Hung
  • Mapks as Modifiers of the Rac, Axin, and Beta-Catenin Pathways and Methods of Use
    Publication number: 20080229435
    Abstract: Human MAPK genes are identified as modulators of the Rac, axin, and beta-catenin pathways, and thus are therapeutic targets for disorders associated with defective Rac, axin, and beta-catenin function. Methods for identifying modulators of Rac, axin, and beta-catenin, comprising screening for agents that modulate the activity of MAPK are provided.
    Type: Application
    Filed: November 24, 2003
    Publication date: September 18, 2008
    Applicant: EX-ELIXIS, INC
    Inventors: Lisa C. Kadyk, George Ross Francis, Steven Brian Gendreau, Emery G. Dora, Michael R. Costa, Kim Lickteig
  • Animal models and methods for analysis of lipid metabolism and screening of pharmaceutical and pesticidal agents that modulate lipid metabolism
    Patent number: 6781028
    Abstract: Drosophila melanogaster and C. elegans that have been genetically modified to express or mis-express proteins involved in the sterol regulatory element binding protein (SREBP) pathway are described. These genetically modified animal models have identifiable phenotypes that make them useful in assays for studying lipid metabolism, other genes implicated in lipid metabolism, and compounds capable of modulating lipid metabolism pathways. Methods for studying lipid metabolism in living nematodes using fluorescently-labelled fatty acid conjugates, such BODITY™ fatty acid conjugates, are also described. Novel SREBP pathway nucleic acid and protein sequences are also described.
    Type: Grant
    Filed: June 14, 1999
    Date of Patent: August 24, 2004
    Assignee: Exelixis, Inc.
    Inventors: Michael R. Costa, Stephen K. Doberstein, Sarah L. Elson, Kimberly Carr Ferguson, Sheila Akiko Homburger
  • Modulators of RabGGT and methods of use thereof
    Publication number: 20040142888
    Abstract: The present invention provides methods for inducing apoptosis in a cell, the methods generally involving contacting the cell with an agent that reduces the level and/or activity of RabGGT. The present invention further provides methods for treating a disorder related to unwanted cell proliferation in an individual, the methods generally involving administering to the individual an agent that reduces the level and/or activity of RabGGT. The present invention further provides methods for reducing apoptosis in a cell, the methods generally involving increasing the level and/or activity of RabGGT in the cell. The present invention further provides methods for treating disorders associated with excessive apoptosis. The present invention further provides methods for identifying a cell that is amenable to treatment with the methods of the present invention. The present invention further provides methods for modulating a binding event between RabGGT and a RabGGT interacting protein.
    Type: Application
    Filed: August 7, 2003
    Publication date: July 22, 2004
    Inventors: Veeraswamy Manne, Mark Lynch, Petra B. Ross-MacDonald, Terry Stouch, Naomi Laing, Pamela Carroll, Kevin Fitzgerald, Louis J. Lombardo, Michael R. Costa, Mark E. Maxwell, Rachel M. Kindt, Mark R. Lackner, Tak Hung, Carol L. O'Brian, Hai Guang Zhang, Katherine S. Brown, Jae Moon Lee